Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with Elisa.

ELISA mass spectrometry pembrolizumab therapeutic drug monitoring

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
30 May 2021
Historique:
received: 10 05 2021
revised: 25 05 2021
accepted: 26 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 3 6 2021
Statut: epublish

Résumé

Pembrolizumab is a humanized immunoglobulin G4-kappa anti-PD1 antibody used in the treatment of different solid tumors or haematological malignancies. A liquid chromatography coupled with a high resolution mass spectrometry (orbitrap technology) method was fully developed, optimized, and validated for quantitative analysis of pembrolizumab in human plasma. A mass spectrometry assay was used for the first time a full-length stable isotope-labelled pembrolizumab-like (Arginine

Identifiants

pubmed: 34070939
pii: biomedicines9060621
doi: 10.3390/biomedicines9060621
pmc: PMC8229588
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Région Auvergne Rhône-alpes
ID : Madmas project in Proof of concept

Références

Ther Drug Monit. 2018 Oct;40(5):596-601
pubmed: 29847460
J Clin Chem Clin Biochem. 1984 Jun;22(6):431-45
pubmed: 6481307
Talanta. 2021 Mar 1;224:121889
pubmed: 33379098
Nat Commun. 2020 Jul 30;11(1):3801
pubmed: 32732879
Yale J Biol Med. 2011 Dec;84(4):381-9
pubmed: 22180676
Drug Discov Today. 2020 Jan;25(1):223-229
pubmed: 31738877
Clin Vaccine Immunol. 2017 May 5;24(5):
pubmed: 28274937
Clin Cancer Res. 2015 Oct 1;21(19):4286-93
pubmed: 25977344
Nat Struct Mol Biol. 2015 Dec;22(12):953-8
pubmed: 26595420
J Immunother Cancer. 2017 May 16;5:43
pubmed: 28515943
J Pharm Biomed Anal. 2017 May 30;139:30-36
pubmed: 28260630
Hematol Oncol. 2020 Dec;38(5):726-736
pubmed: 32786092
Ther Drug Monit. 2019 Oct;41(5):640-647
pubmed: 31584927
J Pharm Biomed Anal. 2019 Feb 5;164:128-134
pubmed: 30368118
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jun 15;1023-1024:9-16
pubmed: 27155936
Bioanalysis. 2009 Nov;1(8):1375-88
pubmed: 21083085
Eur J Cancer. 2020 May;131:68-75
pubmed: 32305010
Nat Commun. 2016 Oct 31;7:13354
pubmed: 27796306
Anal Chim Acta. 2018 Aug 17;1019:93-102
pubmed: 29625688
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32245016
Lancet. 1986 Apr 19;1(8486):908-9
pubmed: 2870372
Clin Transl Oncol. 2021 Feb 13;:
pubmed: 33583005
Oncologist. 2020 Aug;25(8):650-e1145
pubmed: 32134163
Eur J Cancer. 2020 Mar;128:119-128
pubmed: 32037060

Auteurs

Aurélien Millet (A)

Biochemistry and Pharmacology-Toxicology Laboratory, Lyon-Sud Hospital, Hospices Civils de Lyon, F-69495 Pierre Bénite, France.

Nihel Khoudour (N)

Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM 75014 Paris, France.

Jérôme Guitton (J)

Biochemistry and Pharmacology-Toxicology Laboratory, Lyon-Sud Hospital, Hospices Civils de Lyon, F-69495 Pierre Bénite, France.
Toxicology Laboratory, Faculty of Pharmacy ISPBL, University of Lyon 1, F-69373 Lyon, France.

Dorothée Lebert (D)

Promise Proteomics, 7 Parvis Louis Néel, F-38040 Grenoble, France.

François Goldwasser (F)

Department of Medical Oncology, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France.

Benoit Blanchet (B)

Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM 75014 Paris, France.

Christelle Machon (C)

Biochemistry and Pharmacology-Toxicology Laboratory, Lyon-Sud Hospital, Hospices Civils de Lyon, F-69495 Pierre Bénite, France.
Analytical Chemistry Laboratory, Faculty of Pharmacy ISPBL, University Lyon 1, F-69373 Lyon, France.

Classifications MeSH